student
Peking University First Hospital, China
My name is Zhang Chi, a doctoral candidate in the Peking University First Hospital in Beijing China, majoring in infectious diseases. My research interest are the immune pathogenesis of chronic hepatitis B, epidemiology of infectious diseases, and COVID-19. As the first or co-first author, I have published 10+ SCI papers in recent 5 years , including 7 in JCR Q1. one of my article has been citeing more than 1100 times over the past 3 years, named “Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. (Int J Antimicrob Agents. 2020;55(5):105954 .)”.